Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 199

Sort by

Sort Order Select

Journal Articles

Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies

Fnu Amisha, Jessica Shostak, Wenyi Fan, Onyee Chan, Rory Shallis, Zhuoer Xie, Alison Walker, Sameh Gaballa, Javier Pinilla-Ibarz, Eric Padron, David Sallman, Bijal Shah, Julio Chavez, Rami Komrokji, Jeffrey Lancet, Mohammad Hussaini, Yumeng Zhang, Todd Knepper, Andrew Kuykendall

Blood (2025) 146 (Supplement 1): 3531.

https://doi.org/10.1182/blood-2025-3531

Published: 2025

Journal Articles

Real-world changes in CLL treatment patterns following collaborative educational initiatives delivered in community settings

Carmine Deluca, Michael Beyer, Marina Wanes, Catherine Coombs, Deborah Stephens, Lee Jamison, Javier Pinilla-Ibarz, Meghan Thompson, Nitin Jain, Brett Blum, Hejiang Wu, Renee Pearl

Blood (2025) 146 (Supplement 1): 6430.

https://doi.org/10.1182/blood-2025-6430

Published: 2025

Journal Articles

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience

Fnu Amisha, Syeda Saba Kareem, Kiranpreet Kaur, Biwei Cao, Samuel Reynolds, Yumeng Zhang, Celeste Bello, Leidy Isenalumhe, Sameh Gaballa, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Javier Pinilla-Ibarz, Lubomir Sokol, Bijal Shah, Frederick Locke, Julio Chavez, Michael Jain

Blood (2025) 146 (Supplement 1): 5512.

https://doi.org/10.1182/blood-2025-5512

Published: 2025

Journal Articles

Real-world outcomes of Y90-ibritumomab tiuxetan (Zevalin) in low-grade B-cell non-Hodgkin lymphoma: A single-institution experience

Abida Babu, syeda mahrukh naqvi, Julio Chavez, Bijal Shah, Celeste Bello, Leidy Isenalumhe, Sameh Gaballa, Yumeng Zhang, Javier Pinilla-Ibarz, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2025-1825

Published: 2025

Journal Articles

Real world outcomes of asciminib in relapsed/refractory Philadelphia chromosome positive B-ALL and blast Phase CML

Kriti Gera, Jasmine Nadayil, Katherine Tobon, Syeda Saba Kareem, Onyee Chan, Kendra Sweet, Rawan Faramand, Javier Pinilla-Ibarz, Bijal Shah

Blood (2025) 146 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2025-3357

Published: 2025

Journal Articles

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Yumeng Zhang, Fatima Tuz Zahra, Daniel DeAvila, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Abu-Sayeef Mirza, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Lubomir Sokol, Frederick Locke, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 2767.

https://doi.org/10.1182/blood-2025-2767

Published: 2025

Journal Articles

Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns, and age disparities in the United States

Javier Pinilla-Ibarz, Swetha Challagulla, Qianhong Fu, Pengfei Cheng, Mei Xue, Keri Yang

Blood (2025) 146 (Supplement 1): 2762.

https://doi.org/10.1182/blood-2025-2762

Published: 2025

Journal Articles

Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study

Nitin Jain, Catherine Coombs, James D'Olimpio, Nirav Shah, Jacqueline Barrientos, Seung Tae Lee, Danielle Brander, John Nemunaitis, Andrew Gillis-Smith, Shuo Ma, Shirou Kirita, Koji Yoshida, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, William Wierda, Varsha Gandhi, Javier Pinilla-Ibarz

Blood (2025) 146 (Supplement 1): 3892.

https://doi.org/10.1182/blood-2025-3892

Published: 2025

Journal Articles

Optimizing adherence to oral CLL therapies in community oncology centers: Key findings from a quality improvement initiative

Javier Pinilla-Ibarz, Brian Koffman, M. Sarfraz Nawaz, Ralph Vincent Boccia, David Kahn, Emily Zyborowicz, Jeffrey Carter, Cherilyn Heggen, Shelby Sullivan, Lindsay Gurska

Blood (2025) 146 (Supplement 1): 2624.

https://doi.org/10.1182/blood-2025-2624

Published: 2025

Journal Articles

Heterogeneity of circulating CD57+ cytotoxic cell subsets across disease stage and aggressiveness in cutaneous T cell lymphoma

Sara Niyazi, Ahmed Arfa, Tobi Ozoya, Kimberly Ward, Lalith Roopesh, Jeffrey West, Javier Pinilla-Ibarz, Ling Zhang, Lubomir Sokol, Dietrich Werner Idiaquez, Christopher Ryder, Yumeng Zhang

Blood (2025) 146 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2025-3644

Published: 2025

Journal Articles

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 798.

https://doi.org/10.1182/blood-2025-798

Published: 2025

Journal Articles

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Blood (2025) 146 (Supplement 1): 904.

https://doi.org/10.1182/blood-2025-904

Published: 2025

Journal Articles

Dynamic changes in the bone marrow niche following CD19-targeted CAR-T cell infusion in diffuse large B cell lymphoma (DLBCL).

Timothy Shaw, Melanie Mediavilla Varela, Alyssa Obermayer, Rocco English, Xiaoqing Yu, Jose Alejandro-Guevara, Jorge Mansilla-Soto, Jose Conejo-Garcia, Paulo Rodriguez, Eva Sahakian, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 5881.

https://doi.org/10.1182/blood-2025-5881

Published: 2025

Journal Articles

Impact of radiation in limited stage diffuse large B-cell lymphoma in the modern era

Juan Ramirez, Daniel DeAvila, Elisa Galdamez, Cynthia Gwede, Javier Pinilla-Ibarz, Yumeng Zhang, Julio Chavez

Blood (2025) 146 (Supplement 1): 1896.

https://doi.org/10.1182/blood-2025-1896

Published: 2025

Journal Articles

Treatment related outcomes of very old (>85 years) diffuse large b-cell lymphoma patients.

Sushmita Khadka, Anushi Patel, Jonathan Zhao, Leidy Isenalumhe, Lubomir Sokol, Sameh Gaballa, Yumeng Zhang, Celeste Bello, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 1882.

https://doi.org/10.1182/blood-2025-1882

Published: 2025

Journal Articles

Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)

Yumeng Zhang, Jongphil Kim, Richard Corona, Shannen Whiddon, Janice Bennett, Anthony Suda, Bijal Shah, Celeste Bello, Julio Chavez, Leidy Isenalumhe, Sameh Gaballa, Javier Pinilla-Ibarz, Frank Glass, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2025-1881

Published: 2025

Journal Articles

Rare cancer, rare survivors: A 20-year single-center review of adult T-cell lymphoma/leukemia treatment outcomes

Yumeng Zhang, Hayder Saeed, Amin Azem, Jose Sandoval-Sus, Fatima Tuz Zahra, Kavita Ghia, Abu-Sayeef Mirza, Bijal Shah, Celeste Bello, Javier Pinilla-Ibarz, Ling Zhang, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 7161.

https://doi.org/10.1182/blood-2025-7161

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Fatima Tuz Zahra, Yumeng Zhang, Sameh Gaballa, Celeste Bello, Samuel Reynolds, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Hayder Saeed, Aleksandr Lazaryan, Abu-Sayeef Mirza, Lubomir Sokol, Bijal Shah, Frederick Locke, Michael Jain, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2025-4555

Published: 2025

Journal Articles

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Blood (2025) 146 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2025-4537

Published: 2025

Journal Articles

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Yumeng Zhang, Daniel DeAvila, Fatima Tuz Zahra, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Leidy Isenalumhe, Lubomir Sokol, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 8017.

https://doi.org/10.1182/blood-2025-8017

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies

Real-world changes in CLL treatment patterns following collaborative educational initiatives delivered in community settings

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience

Real-world outcomes of Y90-ibritumomab tiuxetan (Zevalin) in low-grade B-cell non-Hodgkin lymphoma: A single-institution experience

Real world outcomes of asciminib in relapsed/refractory Philadelphia chromosome positive B-ALL and blast Phase CML

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns, and age disparities in the United States

Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study

Optimizing adherence to oral CLL therapies in community oncology centers: Key findings from a quality improvement initiative

Heterogeneity of circulating CD57+ cytotoxic cell subsets across disease stage and aggressiveness in cutaneous T cell lymphoma

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Dynamic changes in the bone marrow niche following CD19-targeted CAR-T cell infusion in diffuse large B cell lymphoma (DLBCL).

Impact of radiation in limited stage diffuse large B-cell lymphoma in the modern era

Treatment related outcomes of very old (>85 years) diffuse large b-cell lymphoma patients.

Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)

Rare cancer, rare survivors: A 20-year single-center review of adult T-cell lymphoma/leukemia treatment outcomes

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only